



En Fi De LH1.4  
Product Code:  
HX9904

English

**INTENDED USE - Research Use Only**

DOAC-Stop can be used to efficiently extract all types of Direct Oral Anti-Coagulants (DOACs) including dabigatran, apixaban, rivaroxaban and edoxaban, from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. This product is intended for research use only in the U.S. and Canada.

**INTRODUCTION**

DOAC research is increasing. DOACs are known to interfere with almost all clotting tests to varying degrees and sometimes subjects who need to be tested for underlying coagulation defects may also be on DOACs.

Specific antidotes for individual DOACs are being developed for therapeutic use but are not yet widely available for laboratory use. DOAC-Stop is the first general agent available for solving the research problems associated with DOACs. After addition of DOAC-Stop, plasma samples can be analysed for underlying coagulation defects such as factor deficiencies, heparin, lupus anticoagulant or other interfering antibodies.

**CONTENTS OF PRODUCT**

Product Code	Pack Size
HX9904-20	20 tablets
HX9904-50	50 tablets
HX9904-100	100 tablets
HX9904-200	200 tablets

**LIMITATIONS**

DOAC-Stop may extract low molecular weight compounds resembling DOACs from plasmas. Those affecting coagulation (but administered intravenously, not orally) include argatroban, aprotinin, protamine, hirudin analogues, polymyxin and related cationic compounds.

**PRECAUTIONS**

DOAC Stop is intended for use with plasma samples suspected to contain DOACs. If test results are unchanged by DOAC Stop and DOACs are still suspected to be present, apply appropriate chromogenic anti factor Xa or anti thrombin assays to obtain specific DOAC results. Contact your distributor or manufacturer for technical support.

Store in a dry area at room temperature. Do not use after the expiry date indicated on the label. Treat all biological material as potentially infectious and dispose in accordance with local operating regulations. For further information, please refer to Safety Data Sheet and Product Information.

**INSTRUCTIONS FOR USE**

*Sample preparation:* DOAC-Stop has been developed for use with citrated plasmas. Follow your validated laboratory procedures for preparing test plasma. Apply the citrated plasma in the procedure below to remove any DOAC if present.

Method for DOAC removal from a test plasma:

1.	Add 1.0mL of citrated test plasma to be treated to a plastic centrifuge tube. <i>Ideally 1.0mL plasma but a range from 0.5ml to 1.5ml is acceptable.</i>
2.	Add 1 DOAC-Stop mini-tab and mix gently until it has dispersed. Mix for a further 5 minutes.
3.	Centrifuge down the particulate matter (for example, 5 minutes at 2000g or 1 minute at 7000g in a microfuge). Do not stop centrifuging too quickly.
4.	The supernatant plasma, now depleted of DOACs can be used directly for testing or can be transferred into a separate plastic tube for frozen storage.

**APPLICATION**

Plasmas treated with DOAC-Stop can be used for reliable routine assessment of known blood coagulation parameters. The degree of shortening induced by DOAC-Stop in a clotting time test depends on the concentration and type of DOAC as well as the on the underlying plasma itself. Clotting time results with DOAC sensitive tests such as dRVVT and APTT tests, may be expressed as ratios of test result before (B) to that obtained after (A) DOAC Stop treatment. The B/A result ranges upward from 1.0 and correlates positively with DOAC concentration depending on which DOAC and test is used.

**PERFORMANCE CHARACTERISTICS**

One mini-tab of DOAC Stop in 1.0mL of normal plasma spiked with 500ng/ml of dabigatran, apixaban, rivaroxaban or edoxaban will remove more than 95% of the DOAC within 5 minutes. There was no effect on the baseline APTTs after 3 hours further incubation. In 92 test plasma samples covering a range of abnormalities, 89 gave definitive results and 3 were equivocal after DOAC-Stop in view of sample complexity [1].

A recent study on 135 DOAC-treated plasmas showed that DOAC Stop was mostly effective in overcoming the effects of dabigatran in 40 cases, apixaban in 38 cases, rivaroxaban 42 cases and edoxaban 15 cases on several thrombophilia screening tests. The incidence of false positive lupus anticoagulants fell from approximately 30% to zero [2].










**INDEMNITY NOTICE**

DOAC-Stop is intended to be used with plasma samples containing DOACs. Follow procedures and refer to precautions that may affect the stated or implied claims and performance of this product. Cellabs, Haematex and its agents or distributors are not liable for damages.

## REFERENCES

- [1] Exner T, et al. "Simple method for removing DOACs from plasma samples" Thromb. Res. 2018; 16:1028-39
- [2] Favresse J, et al. Evaluation of the DOAC Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open, 2018; 2: e202-e209.
- [3] Jacquemin M, et al. The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays. Int. J. Lab.Hematol. 2018.
- [4] Kopatz WF, et al. "Use of DOAC Stop for the elimination of anticoagulants in the thrombin generation assay". Thromb. Res. 2018; 170: 97-101.

## EXPLANATION OF SYMBOLS EXPLICATION DES SYMBOLES ERKLAERUNG DER SYMBOLE

	Consult instructions for use Consultez la notice du produit Gebrauchsanleitung konsultieren		Catalogue number Numéro de catalogue Katalognummer
<b>RUO</b>	Research Use Only		Contains sufficient for <n> tests Contient suffisamment de réactifs pour <x> tests Enthält genügend für <n> Tests
	Temperature limitation Limites de température Temperaturbegrenzung		Manufacturer:                   Hersteller: Fabricant : Cellabs, Unit 7/27 Dale St. Brookvale, NSW 2100, Australia
	Keep Dry Conserver au sec Trocken halten		WMDE B. V, Bergerweg 18, 6085 AT Horn, The Netherlands
<b>LOT</b>	Batch code Lot de produit Batch code	Insert version	 LH1.4 09 October 2018
	Expiry Date Date d'expiration Verfallsdatum	